# Effects of PH3 in Diabetic Nephropathy

Study · id `cardio:ct-nct01068041` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01068041](<https://clinicaltrials.gov/study/NCT01068041>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01068041

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT01068041. Randomized; quadruple masking; primary purpose prevention. Start 2010-08 (registry gives no type); primary completion 2014-07 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT01068041, source copy `cardio:ctgov-nct01068041-2026-09-18`, retrieved 2026-10-26)
- Start date: 2010-08 (registry gives no type) (ClinicalTrials.gov record NCT01068041, source copy `cardio:ctgov-nct01068041-2026-09-18`, retrieved 2026-10-26)
- Primary completion: 2014-07 (actual) (ClinicalTrials.gov record NCT01068041, source copy `cardio:ctgov-nct01068041-2026-09-18`, retrieved 2026-10-26)
- Completion: 2015-09 (actual) (ClinicalTrials.gov record NCT01068041, source copy `cardio:ctgov-nct01068041-2026-09-18`, retrieved 2026-10-26)
- Countries: Taiwan (ClinicalTrials.gov record NCT01068041, source copy `cardio:ctgov-nct01068041-2026-09-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01068041-2026-09-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of PH3 in Diabetic Nephropathy
- Acronym: PH3
- Condition: Diabetic Nephropathy
- Intervention (Drug): PH3
- Lead sponsor: PhytoHealth Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: 555433446c7eb9c425d88aef571af13fff8492c82dabc91f3f814ef138e90a7a
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
